ALGINAGRAFT™ is a development-stage composition in which particulate bone graft is carried in an alginate hydrogel of seaweed origin — with no collagen, gelatin or other animal- or human-derived carrier. Handling and performance have not yet been evaluated in testing. This site documents the work as it stands: what is known, what is not, and what the public registries say.
Intraoperative photographs show conventional bone augmentation procedures performed by Dr. Roshkovan. They do not depict ALGINAGRAFT™.
Alginate is extracted from the cell walls of brown algae. No animal tissue, no human donor.
A polysaccharide studied for decades in wound care and cell-encapsulation research.
Calcium ions turn the solution into a cohesive hydrogel at room temperature.
Particulate graft carried inside the gel as one measured unit. A development objective, not a demonstrated result.
Among device listings in active commercial distribution, a putty form accounts for 1.9% of dental bone-graft entries and 11.9% of orthopedic bone-void-filler entries. Same regulator, two categories, one measurable gap.
Not cleared or approved by FDA. No clinical study has begun. Not available for sale or clinical use.
Development status →A granted US and European patent family covers pre-portioned, single-dose bone graft compositions in a dissolvable carrier. The alginate composition is the subject of a pending US application.
Patents & trademark →No ALGINAGRAFT™ data have been published. What exists is the literature on alginate hydrogels and on graft carriers — including results that cut against the concept.
State of evidence →Terminology, US product examples and published findings for collagen, CMC, hyaluronate, gelatin, PEG and alginate carriers in bone graft putty.
Eighteen estimates of the 2025 dental bone graft market span $328 million to $4.41 billion. Which figures rest on audited documents, and which do not.
Putty is 1.9% of active dental bone graft listings in GUDID and 11.9% of orthopedic MQV listings. What FDA's 510(k) and UDI registries show, with queries.
Three ways to stay in touch. None of them is an order form.
An email when bench data, a regulatory step or a publication appears. Nothing else.
Describe a caseWhere does particulate graft come out in your hands — open socket, sinus window, osteotomy? Tell us the scenario.
Future evaluationRegister interest in a future clinical evaluation. No timeline is promised; we will say when one exists.